A STUDY OF ABIRATERONE ACETATE PLUS LOW-DOSE PREDNISONE PLUS ANDROGEN DEPRIVATION THERAPY (ADT) VERSUS ADT ALONE IN NEWLY DIAGNOSED PARTICIPANTS WITH HIGH-RISK, METASTATIC HORMONE-NAIVE PROSTATE CANCER (MHNPC):